07/30
2025
Leadsynbio Rasied over RMB 100 Million in Funding
07/30
Recently, Asia Green Fund's portfolio company, Leadsynbio, closed a new round funding exceeding RMB 100 million, co-led by CICC Capital, Xingxiang Capital, Caixin Capital, and Jiashan Industrial. This investment underscores strong investor confidence in the company’s integrated end-to-end supply chain capabilities and scalable commercialization infrastructure. Proceeds will primarily accelerate new product commercialization and global market penetration.
Leveraging its AI-driven synthetic biology technology platform, Leadsynbio has developed multiple cutting-edge technologies with global competitiveness and established a diversified product pipeline.
The company currently maintains large-scale production of 10+ key raw materials—Human Nutrition, Animal Nutrition, Antibiotic APIs, and Pharmaceutical Intermediates—with products exported to over 20 countries. Its market share continues to demonstrate robust growth.
Going forward, Leadsynbio will deepen its vertically integrated "R&D-Manufacturing-Supply Chain" framework to expedite new product launches, delivering cost-efficient and sustainable bio-based manufacturing solutions worldwide.
Leveraging its AI-driven synthetic biology technology platform, Leadsynbio has developed multiple cutting-edge technologies with global competitiveness and established a diversified product pipeline.
The company currently maintains large-scale production of 10+ key raw materials—Human Nutrition, Animal Nutrition, Antibiotic APIs, and Pharmaceutical Intermediates—with products exported to over 20 countries. Its market share continues to demonstrate robust growth.
Going forward, Leadsynbio will deepen its vertically integrated "R&D-Manufacturing-Supply Chain" framework to expedite new product launches, delivering cost-efficient and sustainable bio-based manufacturing solutions worldwide.